Skip to main content
padlock icon - secure page this page is secure

Free Content Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

In cystic fibrosis (CF), absorption of tacrolimus through the gastrointestinal tract may be impaired due to fat malabsorption. The aim of this pilot study was to compare tacrolimus pharmacokinetics and inter- and intrasubject variability of exposure in stable lung transplant recipients with and without CF, and to determine the best single-time predictors of exposure. The study included 11 lung transplant recipients with CF and 11 without CF who received tacrolimus twice daily. Blood samples were obtained predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h postdose on 3 separate days within 1 week. Tacrolimus pharmacokinetics and inter- and intrasubject variability of exposure were similar in the two groups, though exposure-per-milligram-dose was ∼50% lower in CF patients. Tacrolimus trough concentration did not accurately predict the area under the concentration curve (AUC0–12), but the concentration measured 3 h postdose (C3) was tightly correlated with the AUC0–12 in both CF (r2= 0.86) and non-CF (r2= 0.92) patients. In summary, patients with CF have a higher tacrolimus oral clearance, but nonsignificant differences in short-term inter- and intrasubject variability of exposure compared to patients without CF. C3 is tightly correlated with AUC0–12 in lung transplant recipients with and without CF.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Lung transplantation; pharmacokinetics; tacrolinus

Document Type: Research Article

Affiliations: 1: Departments of Chest Medicine 2: Clinical Chemistry, Erasme University Hospital, Brussels, Belgium 3: Department of Pharmacology, University Hospital, Limoges, France

Publication date: 01 June 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more